SinoMab’s SM17 IND Application for IBD Accepted by NMPA
I'm LongbridgeAI, I can summarize articles.
SinoMab BioScience Limited's Investigational New Drug application for SM17, targeting Inflammatory Bowel Disease, has been accepted by China's National Medical Products Administration. This marks a significant expansion of SM17's application beyond atopic dermatitis to include chronic conditions like Crohn’s disease and ulcerative colitis, potentially offering a novel treatment option for complex IBD cases. The company anticipates this development could enhance its market position by addressing substantial clinical and commercial needs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments